Abstract
In a series of 84 various evaluable disseminated cancer patients treated with hydrazine sulfate as a result of a pharmaceutical-sponsored investigational new drug (IND) study, it was found that 59/84 or 70% of the cases improved subjectively and 14/84 or 17% improved objectively. Subjective responses included increased appetite with either weight gain or cessation of weight loss, increase in strength and improved performance status and decrease in pain. Objective responses included measurable tumor regression, disappearance of or decrease in neoplastic-associated disorders and long-term (over 1 year) 'stabilized condition'. Of the overall 59 subjective improvements 25 (42%) had no concurrent or prior (within 3 months) anticancer therapy of any type. Of the 14 objective improvements 7 (50%) had no concurrent or prior anticancer therapy. Of the remaining cases in which there was either concurrent or prior anticancer therapy, improvements occurred only after the addition of hydrazine sulfate to the treatment regimen. Duration of improvement was variable, from temporary to long-term and continuing. Side effects were mild, comprising for the most part low incidences of extremity paresthesias, nausea, pruritus and drowsiness; there w...Continue Reading
Citations
Jan 3, 2001·Medicinal Research Reviews·J M ArgilésF J López-Soriano
Nov 1, 1993·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·E Bruera
Mar 1, 1995·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·C L Loprinzi
Jan 1, 1995·Investigational New Drugs·V A FilovB A Ivin
Apr 30, 2013·Journal of Molecular Modeling·Pongthep PrajongtatSupa Hannongbua
Dec 24, 2002·Life Sciences·Y C HungG S Huang
Jan 1, 1993·Parasitology·W L Dills
Jan 1, 1981·Nutrition and Cancer·J Gold
Jan 1, 1985·Nutrition and Cancer·A M Lindsey, B F Piper
Jan 1, 1985·Nutrition and Cancer·R T Chlebowski
Jan 1, 1987·Nutrition and Cancer·J Gold
Jan 1, 1997·Nutrition and Cancer·O A Obeid, P W Emery
Jan 8, 2003·Seminars in Oncology·Richard L Nahin
Nov 6, 2007·Expert Opinion on Emerging Drugs·Josep M ArgilésSílvia Busquets
Feb 1, 1983·Experimental Lung Research·D Lagunoff
Dec 16, 1998·Medical Hypotheses·J M Argilés, F J López-Soriano
Jun 5, 2001·Medical Hypotheses·J A Holt
Dec 28, 1999·Medical and Pediatric Oncology·J M Metz
Feb 1, 1992·AIDS Research and Human Retroviruses·M RoedererL A Herzenberg
Feb 1, 1987·Cancer·R T ChlebowskiE Oktay
Sep 1, 1997·Medicinal Research Reviews·J M ArgilésF J López-Soriano
Jan 1, 1985·Cancer·R T Chlebowski
Feb 1, 1986·Seminars in Oncology Nursing·A M Lindsey